The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibitory Effects of GGX on Lung Injury of Chronic Obstructive Lung Disease (COPD) Mice Model

만성폐쇄성폐질환 동물모델에서 GGX의 폐손상 억제 효과

  • Kim, Tae Hyeon (Division of Respiratory Medicine, Dep. of Internal Medicine, College of Korean Medicine, Daejeon University) ;
  • Yang, Won Kyung (Division of Respiratory Medicine, Dep. of Internal Medicine, College of Korean Medicine, Daejeon University) ;
  • Lee, Su Won (Division of Respiratory Medicine, Dep. of Internal Medicine, College of Korean Medicine, Daejeon University) ;
  • Kim, Seung Hyung (Institute of Traditional Medicine and Bioscience, Daejeon University) ;
  • Lyu, Yee Ran (Division of Respiratory Medicine, Dep. of Internal Medicine, College of Korean Medicine, Daejeon University) ;
  • Park, Yang Chun (Division of Respiratory Medicine, Dep. of Internal Medicine, College of Korean Medicine, Daejeon University)
  • 김태현 (대전대학교 한의과대학 폐계내과학교실) ;
  • 양원경 (대전대학교 한의과대학 폐계내과학교실) ;
  • 이수원 (대전대학교 한의과대학 폐계내과학교실) ;
  • 김승형 (대전대학교 동서생명과학연구원) ;
  • 유이란 (대전대학교 한의과대학 폐계내과학교실) ;
  • 박양춘 (대전대학교 한의과대학 폐계내과학교실)
  • Received : 2021.05.03
  • Accepted : 2021.07.28
  • Published : 2021.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This study is aimed to evaluate the protective effects of GGX on lung injury of Chronic Obstructive Lung Disease (COPD) mice model. Materials and Methods: C57BL/6 mice were challenged with lipopolysaccharide (LPS) and cigarette smoke extract (CSE) and then treated with vehicle only (Control group), dexamethasone 3 mg/kg (Dexa group), gam-gil-tang 200 mg/kg (GGT group), GGX 100, 200, and 400 mg/kg (GGX group). After sacrifice, its bronchoalveolar lavage fluid (BALF) or lung tissue was analyzed with cytospin, Enzyme-Linked Immunosorbent Assay (ELISA), real-time polymerase chain reaction (PCR) and hematoxylin & eosin (H&E), and Masson's trichrome staining. Results: In the COPD model, GGX significantly inhibited the increase of neutrophils, TNF-𝛼, IL-17A, CXCL-1, MIP2 in BALF and TNF-𝛼, IL-1𝛽, IL-10 mRNA expression in lung tissue. It also decreased the severity of histological lung injury. Conclusion: This study suggests the usability of GGX for COPD patients by controlling lung tissue injury.

Keywords

Acknowledgement

이 논문은 2019년도 한국연구재단 기초연구사업(과제번호: NRF-2019R1A2C1087201)의 지원을 받아 수행된 연구임.

References

  1. Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY Lee JH, et al. (2018). COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis (Seoul), 81:261-73. https://doi.org/10.4046/trd.2018.0029
  2. Barnes PJ, Shapiro SD, Pauwels RA. (2003). Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J, 22(4):672-88. https://doi.org/10.1183/09031936.03.00040703
  3. Kim IA, Park YB, Yoo KH. (2004). Pharmacotherapy for chronic obstructive pulmonary disease. J Korean Med Assoc, Sep;61(9):545-551. https://doi.org/10.5124/jkma.2018.61.9.545
  4. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. (1994). Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA, 272:1497-505. https://doi.org/10.1001/jama.1994.03520190043033
  5. Singh S, Amin AV, Loke YK. (2009). Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med, 169:219-29. https://doi.org/10.1001/archinternmed.2008.550
  6. Barnes PJ. (2013). New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov, 12(7):543-59. https://doi.org/10.1038/nrd4025
  7. Lee ES, Han JM, Kim MH, Namgung U, Yeo Y, Park YC. (2013). Effects of inhalable microparticles of Socheongryong-tang on chronic obstructive pulmonary disease in a mouse model. J Korean Med, 34(3):54-68. https://doi.org/10.13048/jkm.13012
  8. Lee JG, Yang SY, Kim MH, Namgung U, Park YC. (2011). Protective effects of Socheongryong-tang on elastase-induced lung injury. J Korean Oriental Med, 32(4):83-99.
  9. Kim Y, Yang SY, Kim MH, Namgung U, Park YC. (2011). Effects of Saengmaekcheongpye-eum on LPS-induced COPD model. Korean J Oriental Int Med, 2011;32(2):217-31.
  10. Kim HW, Yang SY, Kim MH, Namgung U, Park YC. (2011). Protective effects of Maekmundong-tang on elastase-induced lung injury. J Korean Oriental Med, 32(2):63-78.
  11. Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S, et al. (2012). Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med, 2012:769830.
  12. Han JM, Yang WK, Kim SH, Park YC. (2015). Effects of Sagan-tang and individual herbs on COPD mice model. J Korean Med Soc Herb Formula Study, 23(2):171-87.
  13. Park JJ, Yang WK, Lyu YR, Kim SH, Park YC. (2019). Inhibitory effects of SGX01 on lung injury of COPD mice model. Korean J Int Korean Med, 40(4):567-81. https://doi.org/10.22246/jikm.2019.40.4.567
  14. Yang WK, Lyu YR, Kim SH, Park YC. (2018). Effects of GHX02 on Chronic Obstructive Pulmonary Disease Mouse Model. J Korean Med, 39(4):126-35. https://doi.org/10.13048/jkm.18040
  15. Kim SH, Hong JH, Yang WK, Geum, et al. (2020). Herbal combinational medication of Glycyrrhiza glabra, Agastache rugosa containing Glycyrrhizic acid, Tilianin inhibits Neutrophilic lung inflammation by affecting CXCL2, Interleukin-17/STAT3 signal pathways in a murine model of COPD. Nutrients, 12(4), 926. https://doi.org/10.3390/nu12040926
  16. Yang, L., Li, J., Li, Y., Tian, Y., Li, S., Jiang, et al. (2015). Identification of metabolites and metabolic pathways related to treatment with Bufei Yishen formula in a rat COPD model using HPLC Q-TOF/MS. Evidence-Based Complementary and Alternative Medicine, 2015.
  17. Hwang DY. (1986). Bang-yak-hap-pyeon. Seoul: Namsandang, p.240.
  18. Lyu YR. (2020). Inhibitory effects of GGX in a particulate matter-induced lung injury mouse model. doctoral dissertation, Daejeon university.
  19. Hong HW. (2011). The Effects of Kamgiltang on Passive Smoking in Rats, doctoral dissertation, Dong-eui University.
  20. Mizutani N, Fuchikami J, Takahashi M, Nabe T, Yoshino S, Kohno S. (2009). Pulmonary emphysema induced by cigarette smoke solution and lipopolysaccharide in guinea pigs. Biol Pharm Bull, 32(9):1559-64. https://doi.org/10.1248/bpb.32.1559
  21. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. (2006). Chronic obstructive pulmonary disease: current burden and future projections. Eur Rspir J, 27(2): 397-412. https://doi.org/10.1183/09031936.06.00025805
  22. Mathers CD, Loncar D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 3(11):e442 https://doi.org/10.1371/journal.pmed.0030442
  23. An TJ Yoon HK. (2018). Prevalence and socioeconomic burden of chronic obstructive pulmonary disease. J Korean Med Assoc, 61(9):533-8. https://doi.org/10.5124/jkma.2018.61.9.533
  24. GBD 2015 Chronic Respiratory Disease Collaborators. (2017). Global, regional, and national deaths, prevalence, disabilityadjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 5(9):691-706. https://doi.org/10.1016/S2213-2600(17)30293-X
  25. Jung YM, Lee H. (2011). Chronic obstructive pulmonary disease in Korea: Prevalence, risk factors, and quality of life. J Korean Acad Nurs, 41(2):149-56. https://doi.org/10.4040/jkan.2011.41.2.149
  26. Ministry of Gender Equality & Family (MOGEF). (2014). 2014 Comprehensive survey on the contact with the harmful environment for youth. Available at: URL: http://www.mogef.go.kr. Accessed April 1.
  27. Yoon J, Seo H, Oh IH, Yoon SJ. (2016). The Non-Communicable Disease Burden in Korea: Findings from the 2012 Korean Burden of Disease Study. J Korean Med Sci, Nov;31 (Suppl 2):S158-S167. https://doi.org/10.3346/jkms.2016.31.S2.S158
  28. Park SK. (2002). Chronic obstructive pulmonary disease - definition, severity, risk factors, etiology, pathology, diagnosis. J Korean Med, 63(2):389-99.
  29. Lurwidya F, Damayanti T, Yunus F. (2016). The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis(Seoul), 79(1):5-13. https://doi.org/10.4046/trd.2016.79.1.5
  30. Lee S, et al. (2007). Antielastin autoimmunity in tobacco smokinginduced emphysema. Nature Med, 13:567-569. https://doi.org/10.1038/nm1583
  31. Yoo CG. (2009). Pathogenesis and pathophysiology of COPD. Korean J Med, 77(4): 383-400.
  32. Barnes PJ. (2004). Macrophages as orchestrators of COPD. COPD, 1:59-70. https://doi.org/10.1081/COPD-120028701
  33. Majo J, Ghezzo H, Cosio MG. (2001). Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J, 17:946-53. https://doi.org/10.1183/09031936.01.17509460
  34. Barnes PJ. (2008). The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest, 118(11):3546-56. https://doi.org/10.1172/JCI36130
  35. Rovina N, Koutsoukou A, Koulouris NG. (2013). Inflammation and immune response in COPD: where do we stand?, Mediators Inflammation, 2013:413735.
  36. Herbology Editorial Committee of Korean Medicine schools. (1991). Boncho-hak. Seoul: Younglimsa, 124-5, 136-7, 214-5, 448-9, 534-5, 580-1, 588-9.
  37. Park YC, Jin M, Kim SH, Kim MH, et al. (2014). Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. Journal of Ethnopharmacology, 151(1), 123-130. https://doi.org/10.1016/j.jep.2013.10.013
  38. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, et al. (1998). Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med, 158(4):1277-85. https://doi.org/10.1164/ajrccm.158.4.9802078
  39. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, et al. (2001). Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163(2):349-55. https://doi.org/10.1164/ajrccm.163.2.2003122
  40. Deveci Y, Deveci F, Ilhan N, Karaca I, Turgut T, Muz MH. (2010). Serum ghrelin, IL-6 and TNF-α levels in patients with chronic obstructive pulmonary disease. Tuberk Toraks, 58(2):162-72.
  41. Traves SL, Donnelly LE. (2008). Th17 cells in airway diseases. Curr Mol Med, 8(5):416-26. https://doi.org/10.2174/156652408785160998
  42. Levanen B, Glader P, Dahlen B, Billing B, Qvarfordt I, Palmberg L, et al. (2016). Impact of tobacco smoking on cytokine signaling via interleukin-17A in the peripheral airways. Int J Chron Obstruct Pulmon Dis, 11:2109-16. https://doi.org/10.2147/COPD.S99900
  43. Lukacs NW, Hogaboam CM, Kunkel SL. (2005). Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy, 4(3):313-7. https://doi.org/10.2174/1568010054022088
  44. Traves SL Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. (2002). Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax, 57(7):590-5. https://doi.org/10.1136/thorax.57.7.590
  45. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, et al. (2003). Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167(1): 24-31. https://doi.org/10.1164/rccm.200204-298OC